CDA | Evidence Driven
CDA | Evidence Driven

nab-paclitaxel

Details

Files
Generic Name:
nab-paclitaxel
Project Status:
Active
Therapeutic Area:
Gastrointestinal cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0360-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination with gemcitabine for the adjuvant treatment of pancreatic cancer.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received12-Feb-2024
Review initiated13-Feb-2024
Expert committee meeting (initial)04-Jul-2024
Draft recommendation posted for stakeholder feedback01-Aug-2024
End of feedback period:16-Aug-2024

Files

Draft Recommendation and Reasons View PDF
Proposed Project Scope View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Stakeholder Input View PDF
Last Updated : August 22, 2024